154 related articles for article (PubMed ID: 31802904)
1. LOXL 2 Promotes The Epithelial-Mesenchymal Transition And Malignant Progression Of Cervical Cancer.
Tian J; Sun HX; Li YC; Jiang L; Zhang SL; Hao Q
Onco Targets Ther; 2019; 12():8947-8954. PubMed ID: 31802904
[TBL] [Abstract][Full Text] [Related]
2. LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing
Peng T; Lin S; Meng Y; Gao P; Wu P; Zhi W; Ding W; Cao C; Wu P
Cell Cycle; 2022 Sep; 21(17):1827-1841. PubMed ID: 35509127
[TBL] [Abstract][Full Text] [Related]
3. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
Salvador F; Martin A; López-Menéndez C; Moreno-Bueno G; Santos V; Vázquez-Naharro A; Santamaria PG; Morales S; Dubus PR; Muinelo-Romay L; López-López R; Tung JC; Weaver VM; Portillo F; Cano A
Cancer Res; 2017 Nov; 77(21):5846-5859. PubMed ID: 28720577
[TBL] [Abstract][Full Text] [Related]
4. Role of LOXL2 in the epithelial-mesenchymal transition and colorectal cancer metastasis.
Park PG; Jo SJ; Kim MJ; Kim HJ; Lee JH; Park CK; Kim H; Lee KY; Kim H; Park JH; Dong SM; Lee JM
Oncotarget; 2017 Oct; 8(46):80325-80335. PubMed ID: 29113306
[TBL] [Abstract][Full Text] [Related]
5. CEBPA facilitates LOXL2 and LOXL3 transcription to promote BCL-2 stability and thus enhances the growth and metastasis of lung carcinoma cells in vitro.
Fan L; Jiang W; Chen C; Gao H; Shi J; Wang D
Exp Cell Res; 2024 Feb; 435(2):113937. PubMed ID: 38242344
[TBL] [Abstract][Full Text] [Related]
6. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
7. LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype.
Cao C; Lin S; Zhi W; Lazare C; Meng Y; Wu P; Gao P; Wei J; Wu P
Front Oncol; 2020; 10():284. PubMed ID: 32211324
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
[TBL] [Abstract][Full Text] [Related]
9. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M
J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025
[TBL] [Abstract][Full Text] [Related]
10.
Yang YL; Tsai MC; Chang YH; Wang CC; Chu PY; Lin HY; Huang YH
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206143
[TBL] [Abstract][Full Text] [Related]
11. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
[TBL] [Abstract][Full Text] [Related]
12. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
13. LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition.
Cuevas EP; Moreno-Bueno G; Canesin G; Santos V; Portillo F; Cano A
Biol Open; 2014 Feb; 3(2):129-37. PubMed ID: 24414204
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
15. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition.
Li SY; Zhang N; Zhang H; Wang N; Du YY; Li HN; Huang CS; Li XR
Cancer Lett; 2024 Jun; 597():216995. PubMed ID: 38851313
[TBL] [Abstract][Full Text] [Related]
17. LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT.
Zhang Q; Yang L; Guan G; Cheng P; Cheng W; Wu A
Front Oncol; 2020; 10():569584. PubMed ID: 33194658
[TBL] [Abstract][Full Text] [Related]
18. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
19. LOXL2 Inhibitors and Breast Cancer Progression.
Ferreira S; Saraiva N; Rijo P; Fernandes AS
Antioxidants (Basel); 2021 Feb; 10(2):. PubMed ID: 33669630
[TBL] [Abstract][Full Text] [Related]
20. Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth.
Weidenfeld K; Schif-Zuck S; Abu-Tayeh H; Kang K; Kessler O; Weissmann M; Neufeld G; Barkan D
Oncotarget; 2016 Nov; 7(44):71362-71377. PubMed ID: 27655685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
